Finding the Path in Nonadvanced Systemic Mastocytosis

Program Description

Nonadvanced systemic mastocytosis (SM) is a rare clonal mast cell disorder that poses diagnostic and therapeutic challenges due to its heterogeneous symptoms, frequent anaphylactic triggers, and requisite of individualized care. This interactive activity follows the journey of Gloria, a fictional patient with indolent SM, as Dr. John Fahrenholz highlights key clinical considerations—including the use of World Health Organization diagnostic criteria, interpretation of KIT D816V testing, risk stratification, and integration of symptom-directed and -targeted therapies. Learners will also hear real-world insights from Laura, a real patient living with SM, who shares how the disease affects her daily life and care decisions. Through this case-based experience, gain practical strategies to improve recognition, diagnosis, and management of nonadvanced SM.

Target Audience

This activity is designed to educate a primary audience of clinical immunology, allergy, and hematology/oncology (hem/oncs), as well as medical dermatology, gastroenterology, and other healthcare providers (HCPs), MDs/DOs, nurse practitioners (NPs), and physician associates (PAs) who manage patients with nonadvanced systemic mastocytosis (SM).

Educational Objectives

Upon completion of this activity, participants should be better able to:

1. Discuss the pathophysiology of nonadvanced systemic mastocytosis (SM), focusing on driver mutations, mast cell hyperactivation, and the scientific rationale for targeted treatments

2. Differentially diagnose nonadvanced SM and classify subtypes using World Health Organization (WHO) or International Consensus Classification (ICC) diagnostic criteria, symptom presentations, biomarkers, and genetic testing

3. Summarize clinical trial findings for emerging and established therapies, including FDA-approved treatments

4. Design personalized treatment plans based on clinical evidence, safety and efficacy considerations, patient-reported outcomes, and shared decision-making

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must:

1. Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Preactivity Questions.
3. Review the activity content.
4. Achieve a grade of at least 70% on the Postactivity Test Questions and complete the Evaluation.

Disclosures of Conflicts of Interest

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

John M. Fahrenholz, MD: Consulting Fees: Cogent; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Blueprint; Contracted Research: Cogent

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.